Objective: To investigate the efficacy of a combination ofStaphylococcus andNeisseria tablets with Budesonide, glycopyrronium bromide, and formoterol fumarate inhalation aerosol in the treatment of childhood bronchial asthma, as well as its effects on intercellular adhesion molecule-1 (ICAM-1), peripheral blood eosinophils (EOS), and lung function.Methods: A total of 80 pediatric patients with bronchial asthma were enrolled and divided into a control group and a combination group according to different treatment methods, with 40 patients in each group. The control group was treated with Budesonide, glycopyrronium bromide, and formoterol fumarate inhalation aerosol, while the combination group received treatment withStaphylococcus andNeisseria tablets in addition to the control group's regimen. Both groups were treated for 3 months. Treatment efficacy, inflammatory indicators [ICAM-1, interleukin-6 (IL-6) levels], immune function indicators [total immunoglobulin E (IgE) and EOS levels], lung function indicators [maximum voluntary ventilation (MVV), forced vital capacity (FVC), and forced expiratory volume in one second (FEV1)], symptom improvement status [Medical Research Council (MRC) dyspnea scale and Asthma Control Test (ACT) scores], and the incidence of adverse reactions were compared between the two groups.Results: The effective rate of the combination group was higher than that of the control group (P0.05).Conclusion: The combination ofStaphylococcus andNeisseria tablets with Budesonide, glycopyrronium bromide, and formoterol fumarate inhalation aerosol demonstrates significant efficacy in treating bronchial asthma. It effectively reduces the severity of airway inflammatory responses, promotes the recovery of immune function, and improves lung function.